US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
GB2324093A
(en)
|
1996-01-04 |
1998-10-14 |
Rican Limited |
Helicobacter pylori bacterioferritin
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
IL139813A0
(en)
|
1998-05-22 |
2002-02-10 |
Loeb Health Res Inst At The Ot |
Methods and products for inducing mucosal immunity
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
WO2001021152A1
(en)
*
|
1999-09-24 |
2001-03-29 |
Smithkline Beecham Biologicals S.A. |
Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
|
AU764368B2
(en)
*
|
1999-09-24 |
2003-08-14 |
Smithkline Beecham Biologicals (Sa) |
Intranasal influenza virus vaccine
|
CA2396871A1
(en)
*
|
2000-01-20 |
2001-12-20 |
Ottawa Health Research Institute |
Immunostimulatory nucleic acids for inducing a th2 immune response
|
KR100919916B1
(ko)
|
2000-02-23 |
2009-10-07 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
종양 특이적 동물 단백질
|
PL206832B1
(pl)
|
2000-05-19 |
2010-09-30 |
Corixa Corp |
Zastosowanie związków opartych na mono- i disacharydach
|
SI1542732T1
(sl)
|
2000-06-20 |
2010-01-29 |
Corixa Corp Csc The United Sta |
Fuzijski proteini Mycobacterium tuberculosis
|
EP1319069B1
(en)
|
2000-06-28 |
2008-05-21 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
AR030829A1
(es)
*
|
2000-10-02 |
2003-09-03 |
Smithkline Beecham Biolog |
Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal
|
EP2189473A3
(en)
|
2000-10-27 |
2010-08-11 |
Novartis Vaccines and Diagnostics S.r.l. |
Nucleic and proteins from streptococcus groups A & B
|
EP2336368A1
(en)
|
2000-12-07 |
2011-06-22 |
Novartis Vaccines and Diagnostics, Inc. |
Endogenous retroviruses up-regulated in prostate cancer
|
US20030072764A1
(en)
*
|
2001-04-05 |
2003-04-17 |
O'hagan Derek |
Mucosal boosting following parenteral priming
|
EP1515982A4
(en)
|
2001-05-09 |
2005-10-26 |
Corixa Corp |
METHODS AND COMPOSITIONS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
|
MY134424A
(en)
*
|
2001-05-30 |
2007-12-31 |
Saechsisches Serumwerk |
Stable influenza virus preparations with low or no amount of thiomersal
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
CN1636015A
(zh)
|
2001-06-29 |
2005-07-06 |
希龙公司 |
Hcv e1e2疫苗组合物
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
DK1581119T3
(da)
|
2001-12-17 |
2013-05-13 |
Corixa Corp |
Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
|
US8088388B2
(en)
|
2002-02-14 |
2012-01-03 |
United Biomedical, Inc. |
Stabilized synthetic immunogen delivery system
|
CA2476626A1
(en)
|
2002-02-20 |
2003-08-28 |
Chiron Corporation |
Microparticles with adsorbed polypeptide-containing molecules
|
US7351413B2
(en)
|
2002-02-21 |
2008-04-01 |
Lorantis, Limited |
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
SE0201701D0
(sv)
*
|
2002-06-05 |
2002-06-05 |
Gotovax Ab |
Treatment of epithelial tumors and infections
|
US8518694B2
(en)
|
2002-06-13 |
2013-08-27 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
|
ATE394671T1
(de)
*
|
2002-07-24 |
2008-05-15 |
Centre Nat Rech Scient |
Verfahren um biologische aktive verbindungen zu identifizieren, die anti-asthmatische und/oder anti-allergische eigenschaften haben
|
US20040132652A1
(en)
*
|
2002-08-30 |
2004-07-08 |
Shire Biochem Inc. |
Pharmaceutical compositions
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
JP4697706B2
(ja)
|
2002-10-11 |
2011-06-08 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン
|
NZ540098A
(en)
|
2002-10-29 |
2008-09-26 |
Coley Pharmaceutical Group Ltd |
Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
|
CA2506318C
(en)
|
2002-11-15 |
2011-07-12 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
EP2263687B1
(en)
|
2002-12-27 |
2015-03-25 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic compositions containing phospholipid
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
ZA200505302B
(en)
|
2003-01-06 |
2007-03-28 |
Corixa Corp |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
EP2191844B1
(en)
|
2003-01-30 |
2014-03-05 |
Novartis AG |
Injectable vaccines against multiple meningococcal serogroups
|
ES2423800T3
(es)
|
2003-03-28 |
2013-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Uso de compuestos orgánicos para la inmunopotenciación
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
WO2004092360A2
(en)
|
2003-04-10 |
2004-10-28 |
Chiron Corporation |
The severe acute respiratory syndrome coronavirus
|
EP2179729B1
(en)
|
2003-06-02 |
2016-07-20 |
GlaxoSmithKline Biologicals SA |
Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
CN103405761A
(zh)
|
2003-10-02 |
2013-11-27 |
诺华疫苗和诊断有限公司 |
多种脑膜炎球菌血清群的液体疫苗
|
JP5030594B2
(ja)
|
2003-12-23 |
2012-09-19 |
アルボー ビータ コーポレーション |
Hpvの発癌性株に対する抗体およびそれらの使用方法
|
CA2559371C
(en)
|
2004-03-09 |
2014-07-08 |
Chiron Corporation |
Influenza virus vaccines
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
EP2272531A3
(en)
|
2004-04-30 |
2011-04-13 |
Novartis Vaccines and Diagnostics S.r.l. |
Integration of meningococcal conjugate vaccination
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
JP4896021B2
(ja)
|
2004-05-21 |
2012-03-14 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
呼吸器系病原体ワクチンのためのアルファウイルスベクター
|
CA2837748C
(en)
|
2004-05-25 |
2016-03-08 |
Oregon Health And Science University |
Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
EP1768662A2
(en)
|
2004-06-24 |
2007-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Small molecule immunopotentiators and assays for their detection
|
US20060165716A1
(en)
|
2004-07-29 |
2006-07-27 |
Telford John L |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
US9034345B2
(en)
|
2005-01-27 |
2015-05-19 |
Children's Hospital & Research Center Oakland |
GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
NZ580974A
(en)
|
2005-02-18 |
2011-05-27 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
LT2351772T
(lt)
|
2005-02-18 |
2016-10-10 |
Glaxosmithkline Biologicals Sa |
Baltymai ir nukleorūgštys iš su meningitu/sepsiu susijusių escherichia coli
|
CA2602637A1
(en)
|
2005-03-31 |
2006-10-05 |
Glaxosmithkline Biologicals Sa |
Vaccines against chlamydial infection
|
CN101237881B
(zh)
*
|
2005-08-03 |
2015-04-22 |
伊缪诺金公司 |
免疫偶联物剂型
|
JP2009511636A
(ja)
|
2005-10-18 |
2009-03-19 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
|
EP1776963A1
(en)
|
2005-10-19 |
2007-04-25 |
Gbf-Gesellschaft Für Biotechnologische Forschung Mbh |
Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
|
DK2368572T3
(da)
|
2005-11-04 |
2020-05-25 |
Seqirus Uk Ltd |
Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur
|
AU2006335256B2
(en)
|
2005-11-22 |
2012-10-18 |
Novartis Vaccines And Diagnostics, Inc. |
Norovirus and sapovirus antigens
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
WO2007085969A2
(en)
|
2006-01-27 |
2007-08-02 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Influenza vaccines containing hemagglutinin and matrix proteins
|
WO2007109813A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
JP2009534303A
(ja)
|
2006-03-24 |
2009-09-24 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー |
冷蔵しないインフルエンザワクチンの保存
|
EP2019686B1
(en)
|
2006-03-31 |
2012-07-11 |
Novartis AG |
Combined mucosal and parenteral immunization against hiv
|
PL2054431T3
(pl)
|
2006-06-09 |
2012-07-31 |
Novartis Ag |
Konformery adhezyn bakteryjnych
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
WO2008020330A2
(en)
|
2006-08-16 |
2008-02-21 |
Novartis Ag |
Immunogens from uropathogenic escherichia coli
|
EP1897557A1
(en)
*
|
2006-09-07 |
2008-03-12 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Use of glycolipids as adjuvants
|
CA3016948A1
(en)
|
2006-09-11 |
2008-03-20 |
Seqirus UK Limited |
Making influenza virus vaccines without using eggs
|
NZ577405A
(en)
|
2006-12-06 |
2012-08-31 |
Novartis Ag |
Vaccines including antigen from four strains of influenza virus
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
MX351247B
(es)
|
2007-04-04 |
2017-10-05 |
Infectious Disease Res Institute Star |
Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
|
CA2692200A1
(en)
|
2007-06-27 |
2008-12-31 |
Novartis Ag |
Low-additive influenza vaccines
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
PL2173376T3
(pl)
|
2007-08-02 |
2015-08-31 |
Biondvax Pharmaceuticals Ltd |
Multimeryczne wieloepitopowe szczepionki przeciwko grypie
|
US20100260791A1
(en)
|
2007-08-03 |
2010-10-14 |
President And Fellows Of Harvard |
Chlamydia antigens
|
US8287885B2
(en)
|
2007-09-12 |
2012-10-16 |
Novartis Ag |
GAS57 mutant antigens and GAS57 antibodies
|
EA201692127A1
(ru)
|
2007-11-07 |
2017-08-31 |
Селлдекс Терапьютикс Инк. |
Антитела, связывающиеся с человеческим dec-205
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
US8637053B2
(en)
|
2007-12-03 |
2014-01-28 |
President And Fellows Of Harvard College |
Chlamydia antigens
|
EP2244695A1
(en)
|
2007-12-07 |
2010-11-03 |
Novartis AG |
Compositions for inducing immune responses
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
WO2009081274A2
(en)
|
2007-12-21 |
2009-07-02 |
Novartis Ag |
Mutant forms of streptolysin o
|
US9579372B2
(en)
|
2008-02-21 |
2017-02-28 |
Glaxosmithkline Biologicals Sa |
Meningococcal fHBP polypeptides
|
EP2631245A1
(en)
|
2008-03-10 |
2013-08-28 |
Children's Hospital & Research Center at Oakland |
Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
|
EP2356225A1
(en)
|
2008-12-03 |
2011-08-17 |
Protea Vaccine Technologies Ltd. |
GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
|
KR101634058B1
(ko)
|
2008-12-09 |
2016-06-27 |
화이자 백신스 엘엘씨 |
IgE CH3 펩티드 백신
|
CN103897045A
(zh)
|
2009-01-12 |
2014-07-02 |
诺华股份有限公司 |
抗革兰氏阳性细菌疫苗中的Cna_B结构域
|
CN102438650A
(zh)
|
2009-03-06 |
2012-05-02 |
诺华有限公司 |
衣原体抗原
|
BRPI1013780B8
(pt)
|
2009-04-14 |
2022-10-04 |
Novartis Ag |
Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
|
BRPI1014494A2
(pt)
|
2009-04-30 |
2016-08-02 |
Coley Pharm Group Inc |
vacina pneumocócica e usos da mesma
|
EP2442826B1
(en)
|
2009-06-15 |
2015-07-08 |
National University of Singapore |
Influenza vaccine, composition, and methods of use
|
WO2011004263A2
(en)
|
2009-07-07 |
2011-01-13 |
Novartis Ag |
Conserved escherichia coli immunogens
|
EP3988115A3
(en)
|
2009-07-15 |
2022-08-17 |
GlaxoSmithKline Biologicals S.A. |
Rsv f protein compositions and methods for making same
|
AU2010272243A1
(en)
|
2009-07-16 |
2012-03-08 |
Novartis Ag |
Detoxified Escherichia coli immunogens
|
KR20130127547A
(ko)
|
2009-07-30 |
2013-11-22 |
화이자 백신스 엘엘씨 |
항원성 타우 펩타이드 및 이의 용도
|
CN104650241A
(zh)
|
2009-08-27 |
2015-05-27 |
诺华股份有限公司 |
包括脑膜炎球菌fHBP序列的杂交多肽
|
NZ620441A
(en)
|
2009-09-03 |
2015-08-28 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
JP2013506651A
(ja)
|
2009-09-30 |
2013-02-28 |
ノバルティス アーゲー |
Staphylococcus.aureus5型および8型莢膜多糖の結合体
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
CA2779816A1
(en)
|
2009-10-27 |
2011-05-05 |
Novartis Ag |
Modified meningococcal fhbp polypeptides
|
JP5917402B2
(ja)
|
2009-11-03 |
2016-05-11 |
タケダ ヴァクシーンズ, インコーポレイテッド |
キメラRSV−Fポリペプチド、およびレンチウイルスGagまたはアルファレトロウイルスGagに基づくVLP
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
WO2011067758A2
(en)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Immunogenic fragments and multimers from streptococcus pneumoniae proteins
|
CA2785585A1
(en)
|
2009-12-22 |
2011-06-30 |
Celldex Therapeutics, Inc. |
Vaccine compositions
|
EP2519265B1
(en)
|
2009-12-30 |
2018-11-14 |
GlaxoSmithKline Biologicals SA |
Polysaccharide immunogens conjugated to e. coli carrier proteins
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
BR112012024348B1
(pt)
|
2010-03-30 |
2022-11-08 |
Children's Hospital & Research Center At Oakland |
Composição imunogênica, seu uso, proteína de ligação ao fator h de ocorrência não natural, e célula bacteriana geneticamente modificada
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011127316A1
(en)
|
2010-04-07 |
2011-10-13 |
Novartis Ag |
Method for generating a parvovirus b19 virus-like particle
|
MX339621B
(es)
|
2010-04-13 |
2016-06-02 |
Celldex Therapeutics Inc * |
Anticuerpos que se unen a cd27 humano y uso de los mismos.
|
EP2558069A1
(en)
|
2010-04-13 |
2013-02-20 |
Novartis AG |
Benzonapthyridine compositions and uses thereof
|
JP2013532008A
(ja)
|
2010-05-28 |
2013-08-15 |
テトリス オンライン インコーポレイテッド |
対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
|
EP2576613A1
(en)
|
2010-06-07 |
2013-04-10 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
WO2011154878A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Ige ch3 peptide vaccine
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
EP2591097A1
(en)
|
2010-07-06 |
2013-05-15 |
Novartis AG |
Norovirus derived immunogenic compositions and methods
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
US20120114688A1
(en)
|
2010-11-08 |
2012-05-10 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
US9352030B2
(en)
*
|
2010-12-14 |
2016-05-31 |
Glaxosmithkline Biologicals, S.A. |
Mycobacterium antigenic composition
|
US20130315959A1
(en)
|
2010-12-24 |
2013-11-28 |
Novartis Ag |
Compounds
|
PL2667892T3
(pl)
|
2011-01-26 |
2019-09-30 |
Glaxosmithkline Biologicals Sa |
Schemat szczepień przeciwko rsv
|
WO2012114323A1
(en)
|
2011-02-22 |
2012-08-30 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
|
EP2680883B1
(en)
|
2011-03-02 |
2018-09-05 |
Pfizer Inc |
Pcsk9 vaccine
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
LT2707385T
(lt)
|
2011-05-13 |
2017-12-11 |
Glaxosmithkline Biologicals Sa |
Iš anksto sulieti rsv f antigenai
|
CA2837651A1
(en)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
EP3508219A1
(en)
|
2011-07-06 |
2019-07-10 |
GlaxoSmithKline Biologicals S.A. |
Self-replicating rna prime - protein boost vaccines
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
US10030052B2
(en)
|
2011-07-25 |
2018-07-24 |
Glaxosmithkline Biologicals Sa |
Parvovirus Vp1 unique region polypeptides and compositions thereof
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2013038385A2
(en)
|
2011-09-14 |
2013-03-21 |
Novartis Ag |
Escherichia coli vaccine combination
|
WO2013084071A2
(en)
|
2011-12-08 |
2013-06-13 |
Novartis Ag |
Clostridium difficile toxin-based vaccine
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
CN104321335A
(zh)
|
2012-02-24 |
2015-01-28 |
诺华股份有限公司 |
菌毛蛋白质和组合物
|
WO2013150518A1
(en)
|
2012-04-01 |
2013-10-10 |
Rappaport Family Institute For Research In The Medical Sciences |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
CN104321078A
(zh)
|
2012-04-26 |
2015-01-28 |
诺华股份有限公司 |
抗原和抗原组合
|
EP2659907A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659908A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659906A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
DK2844282T3
(da)
|
2012-05-04 |
2019-07-15 |
Pfizer |
Prostata-associerede antigener og vaccine-baserede immunterapiregimener
|
SG11201407440WA
(en)
|
2012-05-22 |
2014-12-30 |
Novartis Ag |
Meningococcus serogroup x conjugate
|
EP2869842A1
(en)
|
2012-07-06 |
2015-05-13 |
Novartis AG |
Immunogenic compositions and uses thereof
|
ES2969734T3
(es)
|
2012-08-03 |
2024-05-22 |
Access To Advanced Health Inst |
Composiciones y métodos para tratar una infección activa por Mycobacterium tuberculosis
|
JP2015532276A
(ja)
|
2012-10-02 |
2015-11-09 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
非直鎖状糖コンジュゲート
|
CA2896552A1
(en)
|
2012-10-03 |
2014-04-10 |
Novartis Ag |
Immunogenic compositions
|
PL2925355T3
(pl)
|
2012-11-30 |
2018-06-29 |
Glaxosmithkline Biologicals S.A. |
Antygeny pseudomonas i połączenia antygenów
|
BR112015024860B1
(pt)
|
2013-03-28 |
2023-11-07 |
Access To Advanced Health Institute |
Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
|
CN105263517B
(zh)
|
2013-05-15 |
2021-03-26 |
阿尔伯达大学董事会 |
E1e2hcv疫苗及使用方法
|
EP3616716A3
(en)
|
2014-01-21 |
2020-05-06 |
Pfizer Inc |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
EP3104877B1
(en)
|
2014-02-11 |
2020-01-22 |
The USA, as represented by The Secretary, Department of Health and Human Services |
Pcsk9 vaccine and methods of using the same
|
RU2714248C2
(ru)
|
2014-07-23 |
2020-02-13 |
Чилдрен'З Хоспитал Энд Рисёрч Сентер Эт Окленд |
Варианты фактор н-связывающего белка и способы их применения
|
AR102547A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
|
AR102548A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
|
EP3945096A1
(en)
|
2014-12-19 |
2022-02-02 |
Regenesance B.V. |
Antibodies that bind human c6 and uses thereof
|
CN107427568B
(zh)
|
2015-01-15 |
2021-12-14 |
辉瑞公司 |
用于肺炎球菌疫苗中的免疫原性组合物
|
US20180044429A1
(en)
|
2015-03-09 |
2018-02-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
WO2016191553A1
(en)
|
2015-05-26 |
2016-12-01 |
Ohio State Innovation Foundation |
Nanoparticle based vaccine strategy against swine influenza virus
|
CA2986494A1
(en)
|
2015-06-03 |
2016-12-08 |
Affiris Ag |
Il-23-p19 vaccines
|
US20180186896A1
(en)
|
2015-07-07 |
2018-07-05 |
Affiris Ag |
Vaccines for the treatment and prevention of ige mediated diseases
|
PE20240927A1
(es)
|
2015-07-21 |
2024-04-30 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
|
CA3005524C
(en)
|
2015-11-20 |
2023-10-10 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
AU2017208848A1
(en)
|
2016-01-19 |
2018-07-12 |
Pfizer Inc. |
Cancer vaccines
|
JP7038064B2
(ja)
|
2016-04-18 |
2022-03-17 |
セルデックス セラピューティクス インコーポレイテッド |
ヒトcd40に結合するアゴニスト抗体およびその使用
|
JP2019521095A
(ja)
|
2016-05-21 |
2019-07-25 |
インフェクシャス ディズィーズ リサーチ インスティチュート |
二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
|
WO2018053294A1
(en)
|
2016-09-16 |
2018-03-22 |
Infectious Disease Research Institute |
Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
ES2911490T3
(es)
|
2017-01-20 |
2022-05-19 |
Pfizer |
Composiciones inmunogénicas para su uso en vacunas antineumocócicas
|
US11123415B2
(en)
|
2017-08-16 |
2021-09-21 |
Ohio State Innovation Foundation |
Nanoparticle compositions for Salmonella vaccines
|
AU2018359556B2
(en)
|
2017-11-03 |
2021-12-02 |
Takeda Vaccines, Inc. |
Zika vaccines and immunogenic compositions, and methods of using the same
|
US11633471B2
(en)
|
2018-03-06 |
2023-04-25 |
Unm Rainforest Innovations |
Compositions and methods for reducing serum triglycerides
|
WO2019204462A2
(en)
|
2018-04-17 |
2019-10-24 |
Celldex Therapeutics, Inc. |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
EP3851120A4
(en)
|
2018-09-11 |
2022-04-27 |
Shanghai Public Health Clinical Center |
IMMUNOGEN FOR BROAD-SPECTRUM INFLUENZA VACCINE, AND APPLICATION THEREOF
|
US20220016168A1
(en)
|
2018-12-11 |
2022-01-20 |
Celldex Therapeutics, Inc. |
Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
|
JP2022512345A
(ja)
|
2018-12-12 |
2022-02-03 |
ファイザー・インク |
免疫原性多重ヘテロ抗原多糖-タンパク質コンジュゲートおよびその使用
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
US20220184199A1
(en)
|
2019-04-10 |
2022-06-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
CA3159573A1
(en)
|
2019-11-01 |
2021-05-06 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
CA3165957A1
(en)
|
2020-01-24 |
2021-07-29 |
Thomas K. EQUELS |
Methods, compositions, and vaccines for treating a virus infection
|
JP2021132644A
(ja)
|
2020-02-21 |
2021-09-13 |
ファイザー・インク |
糖の精製
|
PE20230170A1
(es)
|
2020-02-23 |
2023-02-01 |
Pfizer |
Composiciones de escherichia coli y sus metodos
|
CA3189834A1
(en)
*
|
2020-07-24 |
2022-01-27 |
Ronald Levy |
A three component vaccine for covid-19
|
JP2023546615A
(ja)
|
2020-10-27 |
2023-11-06 |
ファイザー・インク |
大腸菌組成物およびその方法
|
AU2021373358A1
(en)
|
2020-11-04 |
2023-06-01 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
US20230405137A1
(en)
|
2020-11-10 |
2023-12-21 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
IL305313A
(en)
|
2021-02-19 |
2023-10-01 |
Sanofi Pasteur |
Recombinant meningococcal B vaccine
|
CA3214853A1
(en)
|
2021-04-09 |
2022-10-13 |
Celidex Therapeutics, Inc. |
Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
|
WO2022234483A1
(en)
|
2021-05-04 |
2022-11-10 |
King Abdullah University Of Science And Technology |
Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
|
US20220387576A1
(en)
|
2021-05-28 |
2022-12-08 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
MX2023013434A
(es)
|
2021-05-28 |
2023-12-12 |
Pfizer Inc |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
|
WO2023079529A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Re-focusing protein booster immunization compositions and methods of use thereof
|
WO2023079528A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
CA3237496A1
(en)
|
2021-11-18 |
2023-05-25 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
KR102420201B1
(ko)
*
|
2022-01-17 |
2022-07-13 |
주식회사 유이케미칼 |
인지질 외피 보유 바이러스 사멸기능을 가지는 친환경 방역 조성물
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2024018061A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Use of bordetella strains for the treatment of chronic obstructive pulmonary disease
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
WO2024110839A2
(en)
|
2022-11-22 |
2024-05-30 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|